Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific.
Adult
Anti-HIV Agents
/ therapeutic use
Anti-Retroviral Agents
/ therapeutic use
Asia
/ epidemiology
Australia
/ epidemiology
Cause of Death
Cohort Studies
Data Management
Databases, Factual
Female
HIV Infections
/ complications
Humans
Male
Middle Aged
Observational Studies as Topic
Proportional Hazards Models
Young Adult
Asia-Pacific
cohort studies
high-income
low-income
mortality
risk factors
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
30
04
2018
accepted:
05
11
2018
entrez:
8
1
2019
pubmed:
8
1
2019
medline:
15
2
2020
Statut:
ppublish
Résumé
AIDS-related deaths in people living with HIV/AIDS have been decreasing in number since the introduction of combination antiretroviral treatment (cART). However, data on recent causes of death in the Asia-Pacific region are limited. Hence, we analysed and compared AIDS-related and non-AIDS-related mortality in high- and low-income settings in the region. Patients from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) receiving cART between 1999 and 2017 were included. Causes of death verification were based on review of the standardized Cause of Death (CoDe) form designed by the D:A:D group. Cohorts were grouped as AHOD (all high-income sites), TAHOD-high (high/upper-middle income countries) and TAHOD-low (lower-middle income countries). TAHOD sites were split into high/upper-middle income and lower-middle income country settings based on World Bank classifications. Competing risk regression was used to analyse factors associated with AIDS and non-AIDS-related mortality. Of 10,386 patients, 522 died; 187 from AIDS-related and 335 from non-AIDS-related causes. The overall incidence rate of deaths during follow-up was 0.28 per 100 person-years (/100 PYS) for AIDS and 0.51/100 PYS for non-AIDS. Analysis indicated that the incidence rate of non-AIDS mortality decreased from 0.78/100 PYS to 0.37/100 PYS from year groups 2003 to 2007 to 2013 to 2017 (p < 0.001). Similarly, incidence rates of AIDS-related deaths decreased from 0.51/100 PYS to 0.09/100 PYS from year groups 2003 to 2007 to 2013 to 2017 (p < 0.001). More recent years of follow-up were associated with reduced hazard for non-AIDS mortality (2008 to 2012: aSHR (adjusted sub-hazard ratio) 0.72, 95% confidence interval (CI) 0.54 to 0.96, p = 0.027; 2013 to 2017: aSHR 0.64, 95% CI 0.47 to 0.87, p = 0.004) compared to years 2003 to 2007. The AHOD cohort had almost twice the hazard of non-AIDS mortality compared to TAHOD-low (lower-middle income sites) (aSHR 1.72, 95% CI, 1.20 to 2.46, p = 0.003); there were no differences between cohorts for AIDS-related mortality (p = 0.834). AIDS and non-AIDS-related mortality rates have decreased over the past years in the Asia-Pacific region. There is a greater risk for non-AIDS-associated deaths in the AHOD cohort compared to lower-middle income settings in TAHOD.
Identifiants
pubmed: 30615271
doi: 10.1002/jia2.25219
pmc: PMC6322485
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25219Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Informations de copyright
© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Lancet. 2014 Sep 13;384(9947):1005-70
pubmed: 25059949
Clin Infect Dis. 2010 May 15;50(10):1387-96
pubmed: 20380565
J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):615-23
pubmed: 19430306
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):342-9
pubmed: 19675463
Arch Intern Med. 2006 Aug 14-28;166(15):1632-41
pubmed: 16908797
J Int AIDS Soc. 2010 Dec 10;13:51
pubmed: 21143940
BMC Infect Dis. 2006 Nov 06;6:159
pubmed: 17087819
J Infect Public Health. 2015 Jan-Feb;8(1):1-10
pubmed: 25294086
J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):555-562
pubmed: 28129256
Lancet HIV. 2016 Aug;3(8):e361-e387
pubmed: 27470028
N Engl J Med. 2007 Apr 26;356(17):1723-35
pubmed: 17460226
Am J Epidemiol. 2007 May 15;165(10):1143-53
pubmed: 17344204
AIDS. 2009 Nov 13;23(17):2323-36
pubmed: 19752715
Oncogene. 2003 Sep 29;22(42):6646-59
pubmed: 14528290
N Engl J Med. 2006 Nov 30;355(22):2283-96
pubmed: 17135583
Antivir Ther. 2015;20(7):731-41
pubmed: 25377928
AIDS. 2012 Jan 28;26(3):335-43
pubmed: 22089374
N Engl J Med. 2003 Nov 20;349(21):1993-2003
pubmed: 14627784
AIDS Res Treat. 2012;2012:375217
pubmed: 22461979
HIV Med. 2013 Feb;14(2):77-84
pubmed: 22934689
Ann Intern Med. 2006 Sep 19;145(6):397-406
pubmed: 16983127
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
HIV Med. 2013 Apr;14(4):195-207
pubmed: 22998068
J Int AIDS Soc. 2019 Jan;22(1):e25219
pubmed: 30615271
JAMA. 1993 Feb 10;269(6):729-30
pubmed: 8093740